NVCT Forex News

Nuvectis Pharma Says FDA Grants Orphan Drug Designation To NXP800 For Cholangiocarcinoma

Biopharmaceutical company Nuvectis Pharma, Inc. (NVCT) announced Thursday that NXP800 was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of cholangiocarcinoma.

RTTNews | 649 days ago

Terms | Privacy | Site Map | Site Map Calendar

HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.

EURUSD	1.13359	GBPUSD	1.35119	AUDUSD	0.64459
USDJPY	144.266	USDCAD	1.37968	USDCHF	0.8272

Advertisement

NVCT Forex News

Nuvectis Pharma Says FDA Grants Orphan Drug Designation To NXP800 For Cholangiocarcinoma